Century Therapeutics, Inc. (IPSC) stock forecast and price target
Price $1.65 · data as of November 13, 2026
12-month price target
Average target$4.75
Upside / downside+187.9%
Analysts4
ConsensusBuy
Low $2.00Average $4.75High $8.00
Gold marker: average target · white marker: today’s price ($1.65)
Analyst ratings
Strong buy 1Buy 3Hold 1Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-0.52 | −1471.0% | $0 |
| Next fiscal year ends December 31, 2027 | $-0.45 | +14.4% | $0 |
| Next quarter ends December 31, 2026 | $-0.12 | +54.0% | $0 |
| Quarter after ends March 31, 2027 | $-0.12 | −9.1% | $0 |
Consensus of the analysts covering Century Therapeutics, updated daily. In the last 30 days 0 estimates were raised and 1 lowered.
Frequently asked questions
What is the Century Therapeutics stock price target?
The average 12-month target from 4 analysts is $4.75, 187.9% above the current price of $1.65 Targets range from $2.00 to $8.00.
Is Century Therapeutics a buy according to analysts?
The consensus rating is “Buy” (1 strong buy, 3 buy, 1 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is Century Therapeutics expected to earn?
Analysts expect EPS of $-0.52 for the fiscal year ending December 31, 2026 and $-0.45 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.